Last updated: November 2, 2026
Orenitram, United Therapeutics’ oral extended-release treprostinil product, has developed into a durable pulmonary arterial hypertension revenue stream. Its commercial position rests on oral convenience, conversion from parenteral prostacyclin therapy, and United Therapeutics’ broader treprostinil franchise. The product faces long-term pressure from generic treprostinil tablets, competing oral therapies such as Uptravi, and United Therapeutics’ own Tyvaso inhaled products.
Orenitram generated approximately $500 million in annual net product revenue in 2024, based on United Therapeutics’ reported product disclosures. Its revenue has increased materially since launch, although growth has moderated as the pulmonary arterial hypertension market has become more competitive and patients have shifted toward inhaled treprostinil products.
What is Orenitram and how does it work?
Orenitram is the extended-release oral tablet formulation of treprostinil, a prostacyclin analogue marketed by United Therapeutics Corporation. The FDA approved Orenitram in December 2013 under New Drug Application 203496 for adults with pulmonary arterial hypertension, or PAH, to delay disease progression and reduce the risk of hospitalization related to worsening PAH.[1]
Treprostinil activates prostacyclin receptors and produces pulmonary and systemic vasodilation. It also inhibits platelet aggregation and has antiproliferative effects on vascular smooth muscle. Orenitram is administered orally, generally two or three times daily depending on the regimen and patient tolerance.
Orenitram product profile
| Attribute |
Detail |
| Active ingredient |
Treprostinil |
| Dosage form |
Extended-release oral tablet |
| Brand owner |
United Therapeutics Corporation |
| FDA approval |
December 20, 2013 |
| NDA |
203496 |
| Primary indication |
Pulmonary arterial hypertension, WHO Group 1 |
| FDA pathway |
New drug application |
| Main competitors |
Uptravi, Tyvaso, Remodulin, generic sildenafil and tadalafil |
| Product category |
Small-molecule prostacyclin analogue |
| Biosimilar exposure |
None |
Orenitram is distinct from Remodulin, which is injectable treprostinil, and Tyvaso, which is inhaled treprostinil. All three products contribute to United Therapeutics’ treprostinil franchise but address different administration and disease-management requirements.
How has Orenitram revenue changed?
Orenitram revenue has expanded from a niche launch product into a material contributor to United Therapeutics’ sales base. Public company filings indicate the following approximate trajectory:
| Fiscal year |
Approximate Orenitram revenue |
Commercial trend |
| 2018 |
$250 million |
Continued physician adoption after launch |
| 2019 |
$290 million |
Growth in oral prostacyclin use |
| 2020 |
$320 million |
Resilient demand despite pandemic disruption |
| 2021 |
$350 million |
Broader use in PAH treatment sequences |
| 2022 |
$390 million |
Continued franchise expansion |
| 2023 |
$450 million to $480 million |
Higher patient demand and price contribution |
| 2024 |
Approximately $500 million |
Mature but still growing product |
The figures reflect rounded company disclosures and may differ from later restatements or product-level presentation changes in United Therapeutics’ annual reports.[2][3]
What drives Orenitram revenue?
Orenitram revenue depends on several commercial variables:
- Growth in the diagnosed PAH population.
- Earlier use of oral prostacyclin therapy.
- Conversion from injectable treprostinil in clinically appropriate patients.
- Persistence and dose escalation.
- Net pricing after rebates and payer discounts.
- Competition from selexipag and inhaled treprostinil.
The product benefits from United Therapeutics’ established PAH sales force and relationships with specialty pharmacies. Its position is stronger in patients who require prostacyclin-pathway treatment but are not ready for continuous infusion therapy.
What is the FDA and Orange Book status of Orenitram?
Orenitram is an FDA-approved small-molecule product listed in the Orange Book under NDA 203496. Its five-year new chemical entity exclusivity expired in December 2018, allowing ANDA applicants to submit abbreviated applications. Patent listings, rather than FDA exclusivity, have been the principal barrier to immediate generic competition.
The FDA label identifies Orenitram for adults with PAH and provides dosing instructions for initiation, titration, interruption, and transition from parenteral treprostinil.[1]
Orenitram regulatory timeline
| Date |
Event |
| December 20, 2013 |
FDA approval of Orenitram |
| December 2018 |
Five-year NCE exclusivity expired |
| 2019 onward |
ANDA filing window opened, subject to Orange Book patents |
| 2021-2024 |
Ongoing product and manufacturing patent protection |
| 2024 |
Product remained commercially marketed by United Therapeutics |
Orenitram is not a biologic. The relevant competitive pathway is an ANDA for generic extended-release treprostinil tablets, not a biosimilar application under the Public Health Service Act.
What patents protect Orenitram?
Orenitram’s principal patent protection relates to extended-release treprostinil formulations, dosage forms, pharmacokinetic performance, and methods of treating PAH. United Therapeutics and affiliated entities have developed a patent estate covering the product’s formulation technology rather than relying solely on composition-of-matter protection.
Publicly identified Orenitram-related patent families include U.S. patents such as US 8,497,393, US 8,945,073, and related continuation patents covering sustained-release treprostinil formulations. Patent expiration dates vary by patent, patent-term adjustment, terminal disclaimers, and Orange Book listing status. The commercially relevant protection has generally extended into the late 2020s.
| Patent category |
Protection target |
Generic relevance |
| Extended-release formulation |
Controlled release of treprostinil |
High |
| Tablet composition |
Excipients, matrix and release profile |
High |
| Pharmacokinetic performance |
Maintaining therapeutic treprostinil exposure |
Medium to high |
| Method of treatment |
Use in PAH and transition regimens |
Medium |
| Manufacturing process |
Production and quality attributes |
Medium |
The formulation claims are more important than the method-of-use claims because an ANDA applicant must show pharmaceutical equivalence and bioequivalence to the reference product. A generic applicant may attempt to design around treatment-method claims while still confronting formulation and product-by-process arguments.
When does Orenitram lose patent exclusivity?
The practical loss of Orenitram exclusivity depends on the validity, enforceability and scope of the remaining listed patents. Regulatory exclusivity ended in 2018, but formulation patents can delay approval or launch into the late 2020s.
A patent’s expiration date does not necessarily equal generic launch timing. A generic company may launch after:
- Patent expiration.
- A final court judgment of invalidity or noninfringement.
- A settlement-based license date.
- A successful Paragraph IV challenge followed by settlement.
- A first-filer exclusivity period, if applicable.
The most credible base case is continued branded protection during the remaining patent term, followed by gradual generic entry rather than an immediate multi-company launch.
Have generic companies filed Paragraph IV challenges to Orenitram?
A Paragraph IV challenge is the primary route for an ANDA applicant to dispute an Orange Book patent before expiration. The applicant certifies that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic product.
Public disclosures concerning Orenitram have not established a broad, publicly documented wave of commercial generic launches. United Therapeutics has historically maintained a strong litigation posture around its PAH products, but the commercial effect of any specific Orenitram challenge depends on the patent claims asserted, the ANDA formulation, and the final court outcome.
Potential generic entrants include large generic manufacturers with cardiovascular or specialty pharmaceutical capabilities. The product’s relatively high value and established oral dosage form make it a logical target, but extended-release formulation development increases technical risk compared with immediate-release tablets.
What generic launch scenarios exist?
| Scenario |
Timing |
Market effect |
| No successful challenge |
After last enforceable patent expires |
Brand retains substantial share until late entry |
| Early settlement license |
Before patent expiration |
Controlled generic entry, often with staged launch |
| Successful Paragraph IV case |
Before patent expiry |
Rapid erosion after court decision |
| At-risk launch |
Before final patent resolution |
High litigation exposure and potential damages |
| Single generic launch |
First entrant receives market advantage |
Moderate price erosion |
| Multiple generic launch |
Several ANDAs enter together |
Accelerated price and volume pressure |
Orenitram is more vulnerable to generic substitution than injectable Remodulin because oral tablets are easier for generic manufacturers to distribute through retail and specialty pharmacy channels. However, payer restrictions, physician preference and the complexity of PAH treatment can slow substitution.
What is the competitive landscape for Orenitram?
Orenitram competes within the prostacyclin pathway and against broader PAH treatment regimens. The most direct branded competitor is Uptravi, or selexipag, marketed by Johnson & Johnson. Tyvaso competes for treprostinil-treated patients who prefer inhaled administration, while Remodulin remains important for patients requiring parenteral therapy.
| Product |
Active ingredient |
Route |
Commercial owner |
Competitive position |
| Orenitram |
Treprostinil |
Oral extended-release |
United Therapeutics |
Oral prostacyclin-pathway therapy |
| Uptravi |
Selexipag |
Oral |
Johnson & Johnson |
Direct oral pathway competitor |
| Tyvaso |
Treprostinil |
Inhaled |
United Therapeutics |
Inhaled alternative within same franchise |
| Remodulin |
Treprostinil |
Injectable |
United Therapeutics |
Advanced or continuous infusion therapy |
| Adempas |
Riociguat |
Oral |
Bayer |
Soluble guanylate cyclase stimulator |
| Letairis |
Ambrisentan |
Oral |
Gilead |
Endothelin receptor antagonist |
| tadalafil and sildenafil |
PDE-5 inhibitors |
Oral |
Multiple |
Lower-cost foundational therapy |
How does Orenitram compare with Uptravi?
Orenitram and Uptravi are both oral therapies used in PAH management, but they have different pharmacology and commercial positioning. Orenitram is a direct treprostinil formulation, while Uptravi is a selective prostacyclin receptor agonist.
Orenitram benefits from United Therapeutics’ established treprostinil franchise and physician familiarity. Uptravi benefits from strong combination-therapy positioning and the commercial infrastructure of Johnson & Johnson. Clinical choice depends on disease severity, tolerability, treatment goals and prior exposure to prostacyclin therapy.
What formulation patents protect Orenitram?
The formulation is central to Orenitram’s value. Treprostinil has a relatively short half-life, so the extended-release tablet must maintain drug exposure across the dosing interval while limiting peak-related adverse effects.
Relevant formulation attributes include:
- Extended drug release.
- Dose proportionality across tablet strengths.
- Consistent absorption.
- Stability during storage.
- Control of peak plasma concentrations.
- Compatibility with food and administration instructions.
- Manufacturing consistency at commercial scale.
The formulation creates a higher technical barrier than an immediate-release generic. An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence while matching the reference product’s release characteristics. Differences in excipient systems or tablet matrices can produce regulatory deficiencies, clinical variability or litigation risk.
What manufacturing and intellectual-property barriers affect generic entry?
Manufacturing risk is concentrated in modified-release tablet production, analytical characterization and scale-up. A generic manufacturer must reproduce the release profile without copying protected formulation claims or relying on an impermissible process.
Key barriers include:
- Complex matrix or coating technology.
- Release testing across multiple strengths.
- Batch-to-batch uniformity.
- Bioequivalence under fed and fasted conditions.
- Stability data.
- Specialized PAH regulatory expertise.
- Limited patient population for large clinical bridging programs.
United Therapeutics also controls commercial distribution relationships and physician education in PAH centers. Those advantages do not prevent generic substitution, but they can preserve branded demand among patients with stable disease and complex titration histories.
What litigation and settlement issues affect Orenitram?
Orenitram litigation risk centers on Orange Book patents and ANDA certifications. The principal legal questions are likely to include:
- Whether the asserted formulation claims are valid.
- Whether the proposed generic infringes the claims.
- Whether continuation patents remain enforceable.
- Whether a generic label can omit patented method-of-use information.
- Whether a settlement permits a licensed entry before patent expiration.
A settlement could establish a confidential or publicly disclosed entry date, authorize a generic from a specific date, or permit an authorized generic arrangement. Such agreements can reduce litigation costs but may materially change the revenue erosion curve.
No confirmed public record establishes a broad commercial Orenitram generic market during the period covered by United Therapeutics’ 2024 reporting. The absence of broad generic penetration supports the view that patent, regulatory or commercial barriers remained material at that time.[2]
What is the revenue exposure if generic Orenitram launches?
Orenitram’s approximately $500 million annual sales make it a meaningful, though not dominant, component of United Therapeutics’ revenue base. The company has greater diversification than it had at launch because Tyvaso and Tyvaso DPI have become major revenue contributors.
A generic launch could affect Orenitram through price reductions, formulary substitution and patient switching. The expected erosion would depend on the number of entrants and the timing of entry.
| Generic-entry outcome |
Potential Orenitram impact |
| One generic with limited distribution |
Gradual price and volume decline |
| Two or more generic entrants |
Faster net-price erosion |
| Authorized generic |
Earlier controlled erosion with possible retained economics |
| Broad payer substitution |
Rapid loss of tablet volume |
| Physician-led continuation |
Slower erosion in stable patients |
| Patent-protected late entry |
Revenue remains resilient until launch |
United Therapeutics can partly offset erosion through Tyvaso, Remodulin and newer pulmonary vascular therapies. Internal franchise substitution is a central factor in assessing Orenitram’s net exposure.
What is the geographic coverage of Orenitram patents?
The core commercial opportunity is concentrated in the United States, where Orenitram has FDA approval and Orange Book-listed protection. International protection depends on national filings, granted patents, supplementary protection mechanisms and local regulatory approvals.
Patent rights for extended-release treprostinil formulations may exist in Europe, Japan, Canada and other markets, but expiration dates and enforceability differ by jurisdiction. International revenue is generally less important than U.S. sales for the product’s overall valuation because the United States is the primary PAH specialty market and the principal source of United Therapeutics’ Orenitram revenue.
How strong is the Orenitram patent estate?
Orenitram has a moderate-to-strong commercial patent estate, but it is less durable than a product protected by an unchallenged composition-of-matter patent.
Strengths include:
- Multiple formulation-related patent families.
- An FDA-approved extended-release dosage form.
- A commercially meaningful product with substantial generic incentive.
- Technical complexity in reproducing release characteristics.
- United Therapeutics’ experience defending treprostinil intellectual property.
Weaknesses include:
- Expired NCE exclusivity.
- Reliance on formulation and method patents.
- Potential design-around strategies.
- The possibility that claims are narrowed or invalidated.
- Eventual exposure to multiple ANDA applicants.
The strongest protection is likely the combination of formulation claims and regulatory difficulty. Method-of-use claims provide supplementary protection but are less reliable when an ANDA applicant can use a skinny label or omit a patented indication.
Key Takeaways
- Orenitram is United Therapeutics’ oral extended-release treprostinil product for pulmonary arterial hypertension.
- FDA approval occurred on December 20, 2013, and five-year NCE exclusivity expired in December 2018.
- Annual revenue reached approximately $500 million by 2024, based on company reporting and rounded product-level estimates.
- The product competes directly with Uptravi and indirectly with Tyvaso, Remodulin and other PAH therapies.
- Orenitram’s main IP protection comes from extended-release formulation and related patent families, with commercially relevant protection extending into the late 2020s.
- Generic entry risk is real but depends on Paragraph IV outcomes, settlements, formulation work and payer substitution.
- Orenitram is a small molecule, so biosimilar risk does not apply.
- Tyvaso and Remodulin provide United Therapeutics with internal franchise diversification if Orenitram faces generic erosion.
FAQs
Is Orenitram a biologic or a small-molecule drug?
Orenitram is a small-molecule drug containing treprostinil. Generic competition proceeds through the ANDA pathway, not the biosimilar pathway.
Is there a generic version of Orenitram?
No broad commercial generic market had been established in the public disclosures reviewed through 2024. Regulatory filings and litigation activity can change before commercial launch.
What is the main patent risk for Orenitram?
The principal risk is invalidation or noninfringement of extended-release formulation patents that protect the tablet’s release profile and composition.
Does Orenitram compete with Tyvaso?
Yes. Both contain treprostinil, but Orenitram is an oral extended-release tablet and Tyvaso is inhaled. They can compete for similar patients while also serving different stages of PAH treatment.
How important is Orenitram to United Therapeutics?
Orenitram is a material product with approximately half a billion dollars in annual sales, but it is smaller than the company’s combined Tyvaso franchise and benefits from diversification across multiple treprostinil delivery systems.
References
-
U.S. Food and Drug Administration. (2024). Orenitram (treprostinil) extended-release tablets prescribing information. FDA.
-
United Therapeutics Corporation. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
United Therapeutics Corporation. (2025). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2024. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
United States Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System records for treprostinil extended-release formulation patents. USPTO.
